跳转至内容
Merck

S1200000

螺内酯

European Pharmacopoeia (EP) Reference Standard

别名:

4-孕烷-21-油酸-17α-醇-3-酮-7α-硫醇γ-内酯7-乙酸盐, 7α-(乙酰硫基)-17α-羟基-3-氧杂戊烯-4-烯-21-羧酸γ-内酯

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H32O4S
CAS号:
分子量:
416.57
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

spironolactone

制造商/商品名称

EDQM

mp

207-208 °C (lit.)

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

InChI key

LXMSZDCAJNLERA-ZHYRCANASA-N

基因信息

human ... NR3C2(4306)

正在寻找类似产品? 访问 产品对比指南

一般描述

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。 如需进一步信息和支持,请访问现行药典网站。

应用

螺内酯EP参考标准品的预期用途是欧洲药典规定的实验室测试。

生化/生理作用

螺内酯是竞争性醛固酮受体拮抗剂。 用作保钾利尿剂。

包装

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他说明

可能适用相应的销售限制。

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Carc. 2 - Repr. 1B - STOT RE 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Patients' interest overlooked.
Prescrire international, 22(139), 148-148 (2013-07-20)
Yang Li et al.
Journal of gastroenterology and hepatology, 35(6), 1069-1077 (2019-12-21)
Emerging evidence suggests aldosterone (aldo) and NLRP3 inflammasome are important factors for HSC activation and liver fibrosis. However, the interaction between aldo and NLRP3 inflammasome in HSC activation and liver fibrosis remains largely unknown. The aim of this study is
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
David End et al.
Cancer research, 73(9), 2926-2926 (2013-04-24)
Adam D Karns et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(3), 186-192 (2013-03-06)
Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension. Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland. In this study, the efficacy
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Lars H Lund et al.
JAMA, 310(2), 205-205 (2013-07-11)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持